Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CALITHERA BIOSCIENCES, INC.

(CALA)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/28 03:02:32 pm
0.418 USD   +2.08%
01/21NORTH AMERICAN MORNING BRIEFING : Dow Wobbles, -3-
DJ
01/20Top Premarket Gainers
MT
01/20SVB Leerink Upgrades Calithera Biosciences to Outperform From Market Perform, Price Target at $3
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/24/2022 01/25/2022 01/26/2022 01/27/2022 01/28/2022 Date
0.4406(c) 0.4413(c) 0.4304(c) 0.4095(c) 0.4129 Last
1 871 291 1 561 593 572 498 1 001 868 705 189 Volume
-2.61% +0.16% -2.47% -4.86% +0.83% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 9,80 M - -
Net income 2021 -62,6 M - -
Net cash position 2021 65,0 M - -
P/E ratio 2021 -0,48x
Yield 2021 -
Sales 2022 1,25 M - -
Net income 2022 -49,6 M - -
Net cash position 2022 24,0 M - -
P/E ratio 2022 -0,63x
Yield 2022 -
Capitalization 30,7 M 30,7 M -
EV / Sales 2021 -3,50x
EV / Sales 2022 5,35x
Nbr of Employees 93
Free-Float 99,2%
More Financials
Company
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company. The CompanyÔÇÖs is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The... 
Sector
Pharmaceuticals
Calendar
03/15Earnings Release
More about the company
Ratings of Calithera Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about CALITHERA BIOSCIENCES, INC.
01/21NORTH AMERICAN MORNING BRIEFING : Dow Wobbles, -3-
DJ
01/20Top Premarket Gainers
MT
01/20SVB Leerink Upgrades Calithera Biosciences to Outperform From Market Perform, Price Tar..
MT
01/11CALITHERA BIOSCIENCES : Investor Deck
PU
01/07AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous ..
PR
01/05CALITHERA BIOSCIENCES : Investor Deck
PU
01/05CALITHERA BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/05Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
GL
01/05Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
GL
2021CALITHERA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listin..
AQ
2021CALITHERA BIOSCIENCES, INC.(NASDAQGS : CALA) dropped from NASDAQ Biotechnology Index
CI
2021Calithera to Present at the 2021 Jefferies London Healthcare Conference
AQ
2021CALITHERA : Q3 Earnings Snapshot
AQ
2021CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
2021Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlight..
PU
More news
News in other languages on CALITHERA BIOSCIENCES, INC.
2021Earnings Flash (CALA) CALITHERA BIOSCIENCES affiche un chiffre d'affaires de 6,8 millio..
2021Calithera rachète deux actifs en phase clinique à Takeda pour renforcer son portefeuill..
2021Calithera Biosciences conclut un accord de licence avec Antengene pour le développement..
2021La perte nette de Calithera Biosciences se réduit au quatrième trimestre
2021CLOSE UPDATE : Les actions finissent en baisse suite au report de la décision de l'OPEP+ s..
More news
Analyst Recommendations on CALITHERA BIOSCIENCES, INC.
More recommendations
Chart CALITHERA BIOSCIENCES, INC.
Duration : Period :
Calithera Biosciences, Inc. Technical Analysis Chart | CALA | US13089P1012 | MarketScreener
Technical analysis trends CALITHERA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,41 $
Average target price 2,50 $
Spread / Average Target 511%
EPS Revisions
Managers and Directors
Susan M. Molineaux President, CEO, CFO & Director
Stephanie Wong Secretary, Chief Financial & Accounting Officer
Francesco Parlati Senior Vice President-Research
Susan B Demo Vice President-Medical Affairs
Emil T. Kuriakose Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CALITHERA BIOSCIENCES, INC.-38.44%31
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960